ES2161278T3 - Factor viii hibrido humano/animal. - Google Patents

Factor viii hibrido humano/animal.

Info

Publication number
ES2161278T3
ES2161278T3 ES95903119T ES95903119T ES2161278T3 ES 2161278 T3 ES2161278 T3 ES 2161278T3 ES 95903119 T ES95903119 T ES 95903119T ES 95903119 T ES95903119 T ES 95903119T ES 2161278 T3 ES2161278 T3 ES 2161278T3
Authority
ES
Spain
Prior art keywords
human
animal
factor viii
subunits
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95903119T
Other languages
English (en)
Inventor
John S Lollar
Marschall S Runge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of ES2161278T3 publication Critical patent/ES2161278T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRODUCE UN FACTOR VIII PROCOAGULANTE HIBRIDO POR EL AISLAMIENTO Y LA RECOMBINACION DE SUBUNIDADES O DOMINIOS DEL FACTOR VIII DE MAMIFEROS HUMANOS Y DE OTROS NO HUMANOS, O POR LA INGENIERIA GENETICA DE LOS GENES DEL FACTOR VIII HUMANOS Y ANIMALES. SE AISLAN LAS SUBUNIDADES O DOMINIOS DEL FACTOR VIII QUE HAN SIDO PURIFICADOS A PARTIR DEL PLASMA HUMANO O ANIMAL, Y SE PRODUCE EL FACTOR VIII HUMANO/ANIMAL HIBRIDO (1) MEZCLANDO SUBUNIDADES DE CADENA PESADA ANIMALES CON SUBUNIDADES DE CADENA LIGERA HUMANAS O MEZCLANDO SUBUNIDADES DE CADENA PESADA HUMANAS CON SUBUNIDADES DE CADENA LIGERA ANIMALES, POR MEDIO DE LOS CUALES SE PRODUCEN MOLECULAS HIBRIDAS DE CADENA LIGERA HUMANA/CADENA PESADA ANIMAL Y CADENA PESADA HUMANA/CADENA LIGERA ANIMAL; O (2) MEZCLANDO UNO O MAS DOMINIOS DE UNA ESPECIE CON UNO O MAS DOMINIOS DE LAS OTRAS ESPECIES. ESTAS MOLECULAS HIBRIDAS SON AISLADAS POR LA CROMATOGRAFIA DE INTERCAMBIO DE IONES. ALTERNATIVAMENTE, LOS METODOS DE ADN RECOMBINANTE, SON USADOS PARA CAMBIAR LOS ELEMENTOS DE FACTOR VIII ANIMAL O DEL FACTOR VIII HUMANO PARA LOS ELEMENTOS CORRESPONDIENTES DEL FACTOR VIII HUMANO O DEL FACTOR VIII ANIMAL, RESPECTIVAMENTE, PARA PRODUCIR UN FACTOR VIII HIBRIDO HUMANO/ANIMAL.
ES95903119T 1994-03-11 1994-11-15 Factor viii hibrido humano/animal. Expired - Lifetime ES2161278T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/212,133 US5663060A (en) 1992-04-07 1994-03-11 Hybrid human/animal factor VIII

Publications (1)

Publication Number Publication Date
ES2161278T3 true ES2161278T3 (es) 2001-12-01

Family

ID=22789694

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95903119T Expired - Lifetime ES2161278T3 (es) 1994-03-11 1994-11-15 Factor viii hibrido humano/animal.

Country Status (11)

Country Link
US (1) US5663060A (es)
EP (1) EP0749444B1 (es)
JP (1) JP3406607B2 (es)
AT (1) ATE204298T1 (es)
AU (1) AU693837B2 (es)
CA (1) CA2185327A1 (es)
DE (1) DE69427997T2 (es)
DK (1) DK0749444T3 (es)
ES (1) ES2161278T3 (es)
PT (1) PT749444E (es)
WO (1) WO1995024427A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
AT403438B (de) * 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6432628B1 (en) * 1997-08-26 2002-08-13 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
US6340740B1 (en) * 1997-08-26 2002-01-22 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
CZ20011021A3 (cs) 1998-09-21 2001-10-17 Genetics Institute, Inc. Způsoby tlumení imunitní odpovědi na terapeutické proteiny
CA2344100A1 (en) * 1998-09-23 2000-03-30 Human Genome Sciences, Inc. 31 human secreted proteins
WO2000032750A1 (en) 1998-11-24 2000-06-08 Regents Of The University Of Minnesota Transgenic circulating endothelial cells
US6770744B2 (en) * 2000-09-19 2004-08-03 Emory University Modified factor VIII
AU2002248329B2 (en) * 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
AU2002337901B2 (en) * 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
EP1454916A1 (en) * 2002-11-29 2004-09-08 ZLB Behring GmbH Modified cDNA factor VIII and its derivatives
EP1424344A1 (en) * 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
CA2579374A1 (en) 2004-09-07 2006-03-30 Archemix Corp. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
EP3243835B1 (en) 2009-02-11 2024-04-10 Albumedix Ltd Albumin variants and conjugates
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
CA2780761A1 (en) 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii t cell epitope variants having reduced immunogenicity
EP2524054A2 (en) * 2010-01-14 2012-11-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
ES2721478T3 (es) 2010-11-05 2019-07-31 Baxalta Inc Nueva variante del factor VIII antihemofílico que tiene actividad específica aumentada
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
AU2016308504A1 (en) 2015-08-20 2018-01-18 Albumedix Ltd. Albumin variants and conjugates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US4868112A (en) * 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
SE468050C (sv) * 1991-03-15 1998-02-11 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins

Also Published As

Publication number Publication date
JP3406607B2 (ja) 2003-05-12
PT749444E (pt) 2001-11-30
AU693837B2 (en) 1998-07-09
US5663060A (en) 1997-09-02
EP0749444B1 (en) 2001-08-16
JPH10500282A (ja) 1998-01-13
ATE204298T1 (de) 2001-09-15
DK0749444T3 (da) 2001-11-26
DE69427997D1 (de) 2001-09-20
DE69427997T2 (de) 2002-04-04
WO1995024427A1 (en) 1995-09-14
CA2185327A1 (en) 1995-09-14
EP0749444A1 (en) 1996-12-27
AU1209695A (en) 1995-09-25

Similar Documents

Publication Publication Date Title
DK0749444T3 (da) Human/dyre-faktor VIII-hybrid
CA2133203A1 (en) Hybrid human/porcine factor viii
NO975674L (no) Fremgangsmåte for å regulere sialyleringen av proteiner fremstilt av pattedyrceller i kultur
DE69636878D1 (de) Zirkuläres DNA Molekül mit einem abhängigen Replikationsursprung, seine Herstellungsverfahren und seine Verwendung in der Gentherapie
ATE403733T1 (de) Künstliche säuger chromosome
DE69131017T2 (de) Optimierung von bindenden proteinen
ATE224908T1 (de) Oligomere phosphoramidat- und phosphorthioamidatverbindungen
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
ATE404684T1 (de) Methoden und zusammensetzungen zur transformation von zellen
ATE266671T1 (de) Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
Takatsuki et al. Structural differences between two types of" heavy chain" disease proteins and myeloma globulins of corresponding types
AU5587298A (en) Isolated mammalian monocyte cell genes; related reagents
IT1303776B1 (it) Processo per la preparazione di genoteche, di polipeptidi utilizzandodette genoteche e i polipepti ottenuti.
ATE196165T1 (de) Methoden zur herstellung von protein c
DK326289D0 (da) Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden
NO175872C (no) Plasmidvektor, fremgangsmåte for fremstilling av peptider og myelomcelle
NZ334146A (en) Generating immortalised chicken cells to be used for propagating virus and producing recombinant proteins
AU7093487A (en) Virus resistant plants having coat protein
BR8603858A (pt) Processo para a producao de hidroxifenil-alcanoato bloqueado de bisfenol a etoxilado,e composicao polimerica estabilizada
AU1695595A (en) Mammalian thymokine genes
BR8600260A (pt) Processo para a preparacao de triacetoxissilanas a partir de tris(amino)silanas
KR960017848A (ko) 인간 적혈구 형성 자극 인자의 신규 제조 방법
PT1117769E (pt) Clonagem e producao recombinante de enzimas de veneno de polistinae, tais como fosfolipase e hialuronidade e terapias imunologicas ai baseadas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 749444

Country of ref document: ES